the aid library

LIST OPTIONS

Filter

2802

Sort by:

Direction:

Download (46)

View PDF (49)

Framework for an Integrated Multisectoral Response to TB, HIV, STIS and Hepatitis in the WHO African Region 2021–2030

World Health Organization WHO (2024) C_WHO

Disability inclusive shelter programming enables persons with disabilities to contribute more to their communities, participate more in consultations and decision-making, and facilitate their own protection. The key concepts include: Disability inclusive shelter programming is both a process and an ... more

Download (105)

View PDF (288)

Health at a Glance: Latin America and the Caribbean 2020

OECD; The World Bank (2020) C1

Thefirst report on Latin America and the Carribean presents key indicators on health and health systems in 33 Latin America and the Caribbean countries. . Analysis is based on the latest comparable data across almost 100 indicators including equity, health status, determinants of health, health car... more

Download (103)

View PDF (125)

Asia Pacific Health Security Action Framework

World Health Organization WHO (2024) C_WHO

Public health emergencies, including pandemics, highlight the need for health systems and services that are prepared, resilient and ready to respond to health security threats. Endorsed by Member States in 2023, the Asia Pacific Health Security Action Framework (‎APHSAF)‎ is designed to engage m... more

Download (131)

View PDF (143)

Building better immunity: A life course approach to healthy longevity

Pan American Health Organization PAHO (2023) C_WHO

As the Americas undergo profound demographic change and there are more persons aged 65 years or older than children younger than 5 years, it is crucial to recognize that national immunization programs must be redesigned to ensure comprehensive protection for individuals across the lifespan. By adopt... more

Download (103)

View PDF (124)

Management and Prevention Strategies for Non-communicable Diseases (NCDs) and Their Risk Factors

Budreviciute, A.; Damiati, S.; Khdr Sabir, D. et al. (2020) CC

Non-communicable diseases (NCDs) are of increasing concern for society and national governments, as well as globally due to their high mortality rate. The main risk factors of NCDs can be classified into the categories of self-management, genetic factors, environmental factors, factors of medical co... more

Download (100)

View PDF (104)

From Panic and Neglect to Investing in Health Security

The World Bank (2017) CC

Multiple pandemics, numerous outbreaks, thousands of lives lost and billions of dollars of national income wiped out—all since the turn of this century, in barely 17 years—and yet the world’s investments in pandemic preparedness and response remain woefully inadequate. We know by now that the ... more

Download (97)

View PDF (226)

Fully fiund the global fund: Get back on track to ende AIDS, TB and Malaria in a Covid world

Global Fund Advocates Network (2021) CC

In 2019, the Global Fund’s 6th Replenishment raised more than $USD14 billion to fight HIV, Tuberculosis and Malaria. Just two years later, the world has changed significantly. Put simply: COVID-19 devastated prevention and treatment programs. For the first time since the Global Fund’s founding, ... more

Download (136)

View PDF (126)

Finanzielle Anstrengungen für die Verwirklichung von SDG 3

Rüppel, J.; Rüppel, T. medmissio (2019) CC

MOBILISIERUNG INLÄNDISCHER ÖFFENTLICHER RESSOURCEN FÜR GESUNDHEIT

Download (246)

View PDF (219)

A checklist for respiratory pathogen pandemic preparedness planning

World Health Organization WHO (2023) C_WHO

This checklist is an operational tool to help national authorities develop or revise national respiratory pathogen (inclusive of influenza and coronaviruses) pandemic preparedness plans.

Download (279)

View PDF (375)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (131)

View PDF (156)

Morbidity management and disability prevention in lymphatic filariasis

World Health Organization (WHO) (2013) C_WHO

The content of these guidelines goes beyond the technicalities of medical needs with additional insights into community empowerment, possible access to welfare and economic opportunities and similar issues. If these are adequately explored, the health and quality of life of people affected and their... more

Download (100)

View PDF (415)

Strategic Plan of Action and Budget 2016 – 2025 for Elimination of Onchocerciasis in Africa

World Health Organization WHO African Prgramme for Onchocerciasis Control (2012) C_WHO

The Strategic Plan of Action and Budget 2016-2025 for the elimination of onchocerciasisin countries was prepared based on the above dlrective for the consideration of IAF 18.The vision of the plan of action is to eliminate onchocerciasis in 80 percent of Africancountries. Implementation of the plan ... more

Download (142)

View PDF (195)

World health statistics 2023: monitoring health for the SDGs, sustainable development goals

World Health Organisation (WHO) (2023) C_WHO

The World health statistics report is the annual compilation of health and health-related indicators which has been published by the World Health Organization (WHO) since 2005. The 2023 edition reviews more than 50 health-related indicators from the Sustainable Development Goals (SDGs) and WHO’s T... more

Download (119)

View PDF (407)

DNDi Strategic Plan 2021-2028 | DNDi - English version

DNDi - Drugs for neglected diseases initiative (2023) C2

Accessed on 04.04.2023 The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected patients

Download (115)

View PDF (297)

Full prescribing information Fexinidazole tablets, for oral use

Drugs for Neglected Diseases initiative DNDi (2021) C1

Full Perscribing information on Fexinidazole Tablet for oral use INDICATIONS AND USAGE Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in pati... more

Download (109)

View PDF (452)

Report of the first WHO stakeholders meeting on rhodesiense human African trypanosomiasis Geneva, 20–22 October 2014

World Health Organization WHO (2014) C_WHO

The objectives of the meeting were: 1. To update the current status of the disease transmission, country capacities and plans for tackling the disease. 2. To understand the epidemiology including disease distribution and risk, the models for estimating under-detection, the geographical variati... more

Download (128)

View PDF (952)

Investigation of the Quality of the 12 Most-Used Antibiotics Available in Retail Private Pharmacies in Rwanda

Bizimana, T.; Kagisha, V.; Nyandwi, J.B: et al. MDPI Antibiotics (2022) CC

Antibiotics 2022, 11(3), 329; https://doi.org/10.3390/antibiotics11030329. The authors found that the most-represented antibiotics on the Rwandan market were amoxicillin, co-trimoxazole and cloxacillin. No counterfeit antibiotics were found in this study. However, substandard batches with moderate ... more

Download (159)

View PDF (190)

Drugs to prevent COVID-19: living guideline

World Health Organisation (WHO) (2023) C_WHO

The WHO Living guideline: Drugs to prevent COVID-19 contains the Organization’s most up-to-date recommendations for the use of drugs to prevent COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform. Guidelines ... more

Download (1559)

View PDF (2388)

The World Medcines situation 2011 Rational use of Medicines

World Health Organization WHO (2011) C_WHO

Millennium Development Goal 8E aims for affordable access to essential medicines. Essential medicines, as defined by WHO, are those that “satisfy the health-care needs of the majority of the population” and that should therefore “be available at all times in adequate amounts”. However, there... more

Download (100)

View PDF (277)

One Health Joint Plan of Action (2022-2026)

World Organisation for Animal Health Food and Agriculture Organization of the United Nations; United Nations Enviroment Programme; Wolrd Health Organization; World Organisation for Animal Health (2022) C_WHO

The desired impact of the OH JPA is a world better able to prevent, predict, detect and respond to health threats and improve the health of humans, animals, plants and the environment while contributing to sustainable development. The OH JPA aims to work towards this vision in the following way: ... more